Suppr超能文献

樟芝通过上调肿瘤抑制 miR-142-3p 增强 5-FU 的化疗敏感性并抑制结肠肿瘤发生和癌症干性。

Antrodia cinnamomea Enhances Chemo-Sensitivity of 5-FU and Suppresses Colon Tumorigenesis and Cancer Stemness via Up-Regulation of Tumor Suppressor miR-142-3p.

机构信息

Department of Surgery, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.

Division of Colorectal Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei 110, Taiwan.

出版信息

Biomolecules. 2019 Jul 25;9(8):306. doi: 10.3390/biom9080306.

Abstract

5-Fluorouracil (5-FU) regimen remains the backbone of the first-line agent to treat colon cancer, but often these patients develop resistance. Cancer stem cells (CSC's) are considered as one of the key contributors in the development of drug resistance and tumor recurrence. We aimed to provide preclinical evidence for (), as a potential in suppressing colon cancer CSC's to overcome 5-FU drug-resistant. In-vitro assays including cell viability, colony formation, + 5-FU drug combination index and tumor sphere generation were applied to determine the inhibitory effect of . Mouse xenograft models also incorporated to evaluate in vivo effect of . treatment significantly inhibited the proliferation, colony formation and tumor sphere generation. also inhibited the expression of oncogenic markers (NF-κB, and C-myc), EMT/metastasis markers (vimentin and MMP3) and stemness associated markers (β-catenin, SOX-2 and Nanog). Sequential treatment of and 5-FU synergized and reduces colon cancer viability both in vivo and in vitro. Mechanistically, mediated anti-tumor effect was associated with an increased level of tumor suppressor microRNAs especially, miR142-3p. can be a potent synergistic adjuvant, down-regulates cancer stemness genes and enhances the antitumor ability of 5-FU by stimulating apoptosis-associated genes, suppressing inflammation and metastasis genes through miR142-3p in colon cancer.

摘要

5-氟尿嘧啶(5-FU)方案仍然是治疗结肠癌的一线药物,但这些患者经常产生耐药性。癌症干细胞(CSC)被认为是导致耐药性和肿瘤复发的关键因素之一。我们旨在为()提供临床前证据,作为抑制结肠癌 CSC 以克服 5-FU 耐药性的潜在药物。应用细胞活力、集落形成、+5-FU 药物联合指数和肿瘤球体生成等体外测定来确定的抑制作用。还将小鼠异种移植模型纳入体内评价的效果。治疗显著抑制了增殖、集落形成和肿瘤球体生成。还抑制了致癌标志物(NF-κB 和 C-myc)、EMT/转移标志物(波形蛋白和 MMP3)和干性相关标志物(β-catenin、SOX-2 和 Nanog)的表达。和 5-FU 的序贯治疗协同作用,降低了体内和体外结肠癌的活力。从机制上讲,介导的抗肿瘤作用与肿瘤抑制 microRNAs 水平的升高有关,特别是 miR142-3p。可以作为一种有效的协同佐剂,通过 miR142-3p 下调癌症干性基因,并通过刺激凋亡相关基因、抑制炎症和转移基因来增强 5-FU 的抗肿瘤能力,从而抑制结肠癌的干性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f27/6723279/46147ca44a6b/biomolecules-09-00306-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验